TETRAPHASE PHARMS
PharmaTETRAPHASE PHARMS is a pharmaceutical company focused on Infectious Disease. Key products include XERAVA.
FDA Novel Drug Designations
(2018)See 1 novel approval →
TETRAPHASE PHARMS at a Glance
- Strong track record with 93% execution quality across 16 trials
- Fast trial execution (12 months median completion)
TETRAPHASE PHARMS's Key Drugs
TETRAPHASE PHARMS's core commercial portfolio centers on XERAVA, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
TETRAPHASE PHARMS's Recent FDA Approvals
New NDA/BLA approvals for TETRAPHASE PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
TETRAPHASE PHARMS's Therapeutic Areas
TETRAPHASE PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TETRAPHASE PHARMS's Top Competitors
TETRAPHASE PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TETRAPHASE PHARMS Pipeline Snapshot
Active clinical trials for TETRAPHASE PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • XERAVA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/4 completed
- • Speed: 12 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-08-27
- Latest
- 2025-03-31
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges